Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background & Aims: Liver stiffness (LS) measurement using transient elastography allows for accurate evaluation of liver fibrosis in patients with chronic liver disease. We aimed to investigate the influence of antiviral treatment using entecavir (ETV) on LS values in patients with chronic hepatitis B (CHB). Methods: 121 patients with CHB who completed a 3-year ETV treatment were recruited. LS values were measured before starting ETV (baseline) and after the completion of the 3-year treatment. A significant decline in the LS value was defined as a ≥30% drop from the baseline. Results: The median baseline LS value of the patients was 14.3 kPa. However, it decreased significantly to 7.3 kPa after 3-year ETV treatment (P < 0.001). A higher baseline LS value was the single independent predictor of a significant decline in LS value on multivariate analysis (P<0.001; hazard ratio [HR], 1.155; 95% confidence interval [CI], 1.073-1.243). Using an optimal cutoff baseline LS value of 11.5 kPa (area under receiver operating characteristic curve, 0.781; 95% CI, 0.698-0.863, P < 0.001; sensitivity 75.6%; specificity, 62.8%), patients with baseline LS values of ≥11.5 kPa had a greater probability of experiencing a significant decline in the LS value than those with baseline LS values of <11.5 kPa (P < 0.001; HR, 5.240; 95% CI, 2.340-11.732). Conclusions: In patients with CHB, LS values were decreased significantly after a 3-year ETV treatment. A higher baseline LS value was the single independent predictor of a significant decline in the LS value.

Original languageEnglish
Pages (from-to)1216-1223
Number of pages8
JournalLiver International
Volume34
Issue number8
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Elasticity Imaging Techniques
Chronic Hepatitis B
Liver
Confidence Intervals
entecavir
Therapeutics
ROC Curve
Liver Cirrhosis

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{3d2c0a55041545c08850ed31cd8eae3d,
title = "Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir",
abstract = "Background & Aims: Liver stiffness (LS) measurement using transient elastography allows for accurate evaluation of liver fibrosis in patients with chronic liver disease. We aimed to investigate the influence of antiviral treatment using entecavir (ETV) on LS values in patients with chronic hepatitis B (CHB). Methods: 121 patients with CHB who completed a 3-year ETV treatment were recruited. LS values were measured before starting ETV (baseline) and after the completion of the 3-year treatment. A significant decline in the LS value was defined as a ≥30{\%} drop from the baseline. Results: The median baseline LS value of the patients was 14.3 kPa. However, it decreased significantly to 7.3 kPa after 3-year ETV treatment (P < 0.001). A higher baseline LS value was the single independent predictor of a significant decline in LS value on multivariate analysis (P<0.001; hazard ratio [HR], 1.155; 95{\%} confidence interval [CI], 1.073-1.243). Using an optimal cutoff baseline LS value of 11.5 kPa (area under receiver operating characteristic curve, 0.781; 95{\%} CI, 0.698-0.863, P < 0.001; sensitivity 75.6{\%}; specificity, 62.8{\%}), patients with baseline LS values of ≥11.5 kPa had a greater probability of experiencing a significant decline in the LS value than those with baseline LS values of <11.5 kPa (P < 0.001; HR, 5.240; 95{\%} CI, 2.340-11.732). Conclusions: In patients with CHB, LS values were decreased significantly after a 3-year ETV treatment. A higher baseline LS value was the single independent predictor of a significant decline in the LS value.",
author = "Kim, {Mi Na} and Seungup Kim and Kim, {Beom Kyung} and Junyong Park and doyoung kim and SangHoon Ahn and KwangHyub Han",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/liv.12377",
language = "English",
volume = "34",
pages = "1216--1223",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir

AU - Kim, Mi Na

AU - Kim, Seungup

AU - Kim, Beom Kyung

AU - Park, Junyong

AU - kim, doyoung

AU - Ahn, SangHoon

AU - Han, KwangHyub

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background & Aims: Liver stiffness (LS) measurement using transient elastography allows for accurate evaluation of liver fibrosis in patients with chronic liver disease. We aimed to investigate the influence of antiviral treatment using entecavir (ETV) on LS values in patients with chronic hepatitis B (CHB). Methods: 121 patients with CHB who completed a 3-year ETV treatment were recruited. LS values were measured before starting ETV (baseline) and after the completion of the 3-year treatment. A significant decline in the LS value was defined as a ≥30% drop from the baseline. Results: The median baseline LS value of the patients was 14.3 kPa. However, it decreased significantly to 7.3 kPa after 3-year ETV treatment (P < 0.001). A higher baseline LS value was the single independent predictor of a significant decline in LS value on multivariate analysis (P<0.001; hazard ratio [HR], 1.155; 95% confidence interval [CI], 1.073-1.243). Using an optimal cutoff baseline LS value of 11.5 kPa (area under receiver operating characteristic curve, 0.781; 95% CI, 0.698-0.863, P < 0.001; sensitivity 75.6%; specificity, 62.8%), patients with baseline LS values of ≥11.5 kPa had a greater probability of experiencing a significant decline in the LS value than those with baseline LS values of <11.5 kPa (P < 0.001; HR, 5.240; 95% CI, 2.340-11.732). Conclusions: In patients with CHB, LS values were decreased significantly after a 3-year ETV treatment. A higher baseline LS value was the single independent predictor of a significant decline in the LS value.

AB - Background & Aims: Liver stiffness (LS) measurement using transient elastography allows for accurate evaluation of liver fibrosis in patients with chronic liver disease. We aimed to investigate the influence of antiviral treatment using entecavir (ETV) on LS values in patients with chronic hepatitis B (CHB). Methods: 121 patients with CHB who completed a 3-year ETV treatment were recruited. LS values were measured before starting ETV (baseline) and after the completion of the 3-year treatment. A significant decline in the LS value was defined as a ≥30% drop from the baseline. Results: The median baseline LS value of the patients was 14.3 kPa. However, it decreased significantly to 7.3 kPa after 3-year ETV treatment (P < 0.001). A higher baseline LS value was the single independent predictor of a significant decline in LS value on multivariate analysis (P<0.001; hazard ratio [HR], 1.155; 95% confidence interval [CI], 1.073-1.243). Using an optimal cutoff baseline LS value of 11.5 kPa (area under receiver operating characteristic curve, 0.781; 95% CI, 0.698-0.863, P < 0.001; sensitivity 75.6%; specificity, 62.8%), patients with baseline LS values of ≥11.5 kPa had a greater probability of experiencing a significant decline in the LS value than those with baseline LS values of <11.5 kPa (P < 0.001; HR, 5.240; 95% CI, 2.340-11.732). Conclusions: In patients with CHB, LS values were decreased significantly after a 3-year ETV treatment. A higher baseline LS value was the single independent predictor of a significant decline in the LS value.

UR - http://www.scopus.com/inward/record.url?scp=84905726524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905726524&partnerID=8YFLogxK

U2 - 10.1111/liv.12377

DO - 10.1111/liv.12377

M3 - Article

C2 - 24267737

AN - SCOPUS:84905726524

VL - 34

SP - 1216

EP - 1223

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 8

ER -